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Survivors of Childhood Brain Tumors (SCBT) are at a higher risk of developing cardiovascular disease
and type 2 diabetes compared to the general population. Adiposity is an important risk factor for the
development of these outcomes, and identifying biomarkers of adiposity may help the stratification
of survivors based on their cardiovascular risk or allow for early screening and interventions to improve
cardiometabolic outcomes. Leptin is an adipokine that positively correlates with the adipose mass
in the general population and is a predictor of adverse cardiometabolic outcomes, yet its association
with adiposity in SCBT has not been studied. The aim of this study was to determine if leptin levels
are associated with the adipose mass in SCBT, and to define its predictors. This cross-sectional study
included 74 SCBT (n = 32 females) with 126 non-cancer controls (n = 59 females). Total adiposity was
measured using Bioelectrical Impendence Analysis (BIA) and central adiposity was measured using
waist-to-hip ratio (WHR) and waist-to-height ratio (WHtR). We used multivariable linear regression
analysis to determine if leptin predicts adiposity in SCBT and adjusted for age, sex, puberty, and cancer
status. Leptin correlated strongly with total (p < 0.001) and central (WHR p = 0.001; WHtR p < 0.001)
adiposity in SCBT and non-cancer controls. In conclusion, leptin is a potential biomarker for adiposity in
SCBT, and further investigation is needed to clarify if leptin is a predictor of future cardiometabolic risk
in SCBT.
Cardiovascular disease is a leading cause of morbidity and mortality, accounting for approximately 17.6 million
deaths per annum globally1,2. While cardiovascular diseases are a significant burden on healthcare systems in
the general population1–4, specific populations seem to have a higher propensity for these diseases than others,
and one such cohort includes the survivors of childhood cancer. Cardiovascular diseases are one of the leading
causes of non-cancer related mortality in this population, and accounts for 20% of mortality rates within 15 years
of cancer therapy5–8.
Within the cancer survivorship subgroups, the Survivors of Childhood Brain Tumors (SCBT) have a significant risk of premature cardiovascular diseases and one of their major risk factors, type 2 diabetes mellitus6,9,10.
SCBT have a 29-fold higher risk for stroke and a two-fold higher risk of type 2 diabetes compared to non-cancer
controls9,11. Cardiometabolic disorders are emerging as an important determinant of longevity and quality of life
in SCBT8, and there is a critical necessity to identify the risk factors and biomarkers of cardiometabolic risk to
personalize preventative and therapeutic strategies to improve outcomes in this population.
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SCBT
(n = 74)

Controls
(n = 126)

Variables

Mean ± SD

Mean ± SD

P-value

Age at enrollment (years)

15.08 ± 7.27

14.04 ± 2.72

0.633

Sex, No. (%)
Male

42 (56.80)

67 (53.20)

—

Female

32 (43.20)

59 (46.80)

—

Height (cm)

151.13 ± 25.22

162.19 ± 15.13

<0.001

Height z-score

−0.24 (−2.6–1.56)

0.28 (−2.01–1.99)

<0.001

Weight (kg)

53.32 ± 24.58

60.09 ± 21.97

0.003

Weight z-score

−0.10(−1.69–2.23)

0.20 (−1.45–4.42)

0.001

BMI percentile (%)

63.54 ± 30.83

63.46 ± 30.37

0.981

Fat mass percentage (%FM) (n = 180)

24.99 ± 9.99

22.68 ± 9.79

0.105

Waist-to-hip ratio (n = 198)

0.87 ± 0.07

0.83 ± 0.10

0.001

Waist-to-height ratio (n = 198)

0.48 ± 0.07

0.45 ± 0.08

0.014

Leptin (ng/ml; n = 47 SCBT, n = 97 controls)

14.74 ± 21.76

10.62 ± 12.11

0.770

Table 1. Study Population Characteristics. Abbreviations: SCBT, survivors of childhood brain tumors; SD,
standard deviation; BMI, Body Mass Index. The data for height and weight z-scores are reported a mean with
range.

The presence of excess adiposity is a major risk factor for cardiovascular diseases and type 2 diabetes mellitus
in the general population12,13. Importantly, SCBT have an important phenotypic difference when compared to
non-cancer controls with excess total and central adiposity in the presence of similar Body Mass Index (BMI)14–18.
This is critically important, as higher adiposity during childhood carries over to adulthood and is associated with
adverse cardiometabolic outcomes in the general population, but the path to excess adiposity is unknown in
SCBT group19–22.
Leptin is an adipokine that serves as a biomarker of the fat mass in the general population23–26, and hyperleptinemia is a predictor of several cardiometabolic outcomes27–31 including diabetes27,28, glucose intolerance29,
insulin resistance29, coronary events30, hypertension31, and features of the metabolic syndrome29. However, the
relationship between leptin levels, adiposity, and cardiometabolic outcomes in SCBT is not known. In this paper,
we tested the hypothesis that leptin is associated with adiposity in SCBT in a similar way to this association in
non-cancer controls. We also set out to define the potential predictors of leptin levels in SCBT.

Results

Demographics. The population characteristics are reported in Table 1. The SCBT group was recruited at
6 ± 4.2 years post completion of cancer therapy, and included 74 SCBT (n = 32 female, 43.20%) and 126 non-cancer controls (n = 59 female, 46.80%). The groups had similar age distribution (SCBT: 15.08 ± 7.27 years; controls:
14.04 ± 2.72 years). SCBT were shorter (SCBT: 151.13 ± 25.22 cm; controls: 162.19 ± 15.13) and had lower weight
(SCBT: 53.32 ± 24.58 kg; controls: 60.09 ± 21.97) compared to non-cancer controls.
There were no differences in BMI percentiles in the two groups (SCBT: 63.54 ± 30.83; controls: 63.46 ± 30.37).
On assessment of adiposity phenotype in participants, total adiposity trended higher in survivors compared
to non-cancer controls measured via fat mass percentage yet this was not statistically significant (%FM; SCBT:
24.99 ± 9.99%; controls: 22.68 ± 9.79%, p-value 0.105). In addition, SCBT had higher central adiposity compared
to non-cancer controls including waist-to-hip ratio (WHR; SCBT: 0.87 ± 0.07, controls: 0.83 ± 0.10, p-value
0.001) and waist-to height ratio (WHtR; SCBT: 0.48 ± 0.07; controls: 0.45 ± 0.08, p-value 0.014). The majority
of both groups have either completed or were undergoing pubertal development (SCBT n = 51, 68.9%, controls
n = 109, 86.5%, p-value 0.005).
Brain tumor characteristics. The characteristics of the tumors in SCBT group are presented in Table 2. The

most common tumor type was low grade glioma (n = 42, 56.80%). Tumors were distributed equally between the
supratentorial (n = 35, 47.30%) and infratentorial (n = 39, 52.70%) regions. The majority of survivors were surgically treated (n = 57, 77.00%), and some had radiotherapy (n = 30, 40.50%) and chemotherapy (n = 36, 48.60%)
as per standard protocols10,32,33. Leptin levels correlated with surgery (r = 0.35, p-value 0.015) and radiotherapy
(r = 0.43, p-value 0.002) but not chemotherapy (r = 0.18, p-value 0.230).

Leptin and adiposity measures in SCBT. To determine if leptin levels were different between SCBT and
non-cancer controls, we measured plasma leptin levels using Enzyme Linked Immunosorbent Assay (ELISA)
technique. The average leptin levels were similar between the two groups (SCBT: 14.74 ± 21.76 ng/ml vs controls:
10.62 ± 12.11 ng/ml, p = 0.770).
To determine if leptin was associated with the fat mass, we performed an unadjusted Pearson zero-order
correlation analysis and an age, sex, and puberty-adjusted partial correlation analysis (Table 3). Leptin correlated
with total adiposity (Unadjusted r = 0.68; Adjusted r = 0.67; p < 0.001). Leptin also correlated with central adiposity measures including a weak positive correlation with WHR (Unadjusted r = 0.19; Adjusted r = 0.29; p < 0.001)
and a strongly positive correlation with WHtR (Unadjusted r = 0.58; Adjusted r = 0.63; p < 0.001).
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Variables

No. (%)

Brain tumor type
Non-NF-1, low grade glioma

31 (41.90)

PNET/Medulloblastoma

16 (21.60)

NF-1, low grade glioma

11 (14.90)

CNS germ cell tumors

6 (8.10)

Subependymal giant cell astrocytoma

3 (4.10)

Ependymoma

2 (2.70)

Meningioma

1 (1.40)

Craniopharyngioma

2 (2.70)

Other

2 (2.70)

Brain tumor location
Supratentorial

35 (47.30)

Infratentorial

39 (52.70)

Brain tumor treatments
Surgery

57 (77.00)

Radiotherapy

30 (40.50)

Chemotherapy

36 (48.60)

Table 2. Brain tumor characteristics (n = 74). Abbreviations: CNS, Central Nervous System; PNET, Primitive
Neuroectodermal Tumor; NF-1, Neurofibromatosis Type 1.

Correlations
Variable

Standardized
coefficient β

Unadjusted
Zero-order

Adjusted
Partial

p-value

Dependent Variable: %FM
Leptin

0.67

0.68

0.67

<0.001

Cancer vs. Control Group

0.18

0.09

0.26

<0.001

Dependent Variable: Waist-to-hip ratio
Leptin

0.30

0.19

0.29

<0.001

Cancer vs. Control Group

0.24

0.25

0.26

<0.001

Dependent Variable: Waist-to-height ratio
Leptin

0.67

0.58

0.63

<0.001

Cancer vs. Control Group

0.17

0.17

0.22

<0.001

Table 3. Regression analyses and correlations of predictors of leptin adjusted for age, sex, puberty, and cancer
status. Abbreviations: BMI, Body Mass Index; CI, confidence interval; %FM, fat mass percentage.

To assess if leptin was associated with the fat mass in SCBT, we conducted multivariable linear regression
analyses (Table 3). Leptin was associated with total adiposity (%FM β = 0.67, p < 0.001) and central adiposity
(WHR β = 0.30, p < 0.001; WHtR β = 0.67, p < 0.001). Furthermore, having a brain tumor was associated with
having a higher %FM (β = 0.18, p < 0.001) as well as central adiposity (WHR β = 0.24, p < 0.001; WHtR β = 0.17,
p < 0.001). Treatments including surgery, radiotherapy, or chemotherapy had no effect on the association between
adiposity and leptin levels (data not shown).
Taken together, these data demonstrated that leptin was a biomarker of total and central adiposity in SCBT
and in non-cancer controls.

Discussion

Up to 80% of children diagnosed with certain subtypes of brain tumors today are likely to survive their diagnosis34, yet the emergence of cardiometabolic disorders in survivors may undermine these survival rates and
contribute to premature mortality35–40. Identifying biomarkers of the fat mass in SCBT may help predict who is
at risk of excess adiposity, a known risk factor for the development of cardiometabolic disorders. The prediction
of adiposity may allow risk stratification and the targeting of those in need of early aggressive interventions to
improve survival and quality of life in survivors.
We demonstrate that leptin was a robust biomarker of total and central adiposity in SCBT, and that this
trend was similar to the one noted in the non-cancer control group. To our knowledge, this is the first report of
leptin assessment in SCBT in comparison to a non-cancer control group across a range of BMIs and adiposity
levels.
In one group of brain tumors, Craniopharyngioma, it has been reported that patients develop hypothalamic
obesity and hyperleptinemia41,42. The latter study by Shaikh et al. included obese participants with additional
subtypes of brain tumors beside Craniopharyngioma, as well as a non-brain tumor group e.g. Histiocytosis,
Retinoblastoma. In a cross-sectional design, the investigators used DXA scans to compare adiposity in the tumors
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group with two other groups-congenital hypopituitarism and simple obesity. The study had a smaller sample size
when compared to our study42. The direct comparisons between our data and this study were limited due to these
differences.
Leptin is a 16 kDa peptide hormone secreted mainly by the adipocyte and is encoded by the obese (OB) gene
in humans that is located on chromosome 723,43. The leptin receptor is preferentially expressed in hypothalamic
nuclei including the ventromedial and dorsomedial nuclei, and the arcuate nucleus44–46, where it plays a critical role in regulating energy homeostasis through its role in satiety regulation and metabolic rate23,47–50. Excess
caloric consumption raises leptin levels which increases energy expenditure while suppressing appetite51,52.
Leptin levels are also sensitive to changes in adiposity53,54. Weight loss leads to a reduction in leptin concentrations, likely due to a reduction in adipose tissue production of the adipokine53,54, and the opposite effect is seen in
obesity55. Accordingly, leptin levels positively correlate with BMI, waist circumference and total adiposity in the
general pediatric and adult populations24–26,56,57. Furthermore, females have higher circulating leptin levels compared to males in children and adults58,59. This makes leptin a potential biomarker of the response to interventions
that target adiposity in SCBT.
While genetic leptin deficiency in humans is associated with early onset obesity60,61, leptin resistance at a
hypothalamic level may play an important role in the development of diet-induced obesity62–65.
Leptin has also served as a biomarker for cardiometabolic outcomes24,25,27–31,56. Leptin levels positively correlate with fasting insulin concentrations25, and it is a predictor of glucose intolerance, insulin resistance and
the metabolic syndrome independently of baseline obesity in the general population29. In men, increased leptin levels are a predictor for developing diabetes independently of basal adiposity, insulin resistance, glucose
or age27. Also, elevated levels of leptin have been shown to be a significant predictor of coronary events30 and
hypertension31.
In children, leptin is also a predictor of BMI, fasting insulin and triglycerides57.
Further research is required to determine if leptin can similarly be used as a potential biomarker to predict
future cardiometabolic outcomes in the SCBT population similarly to the general population.
Leptin is secreted in proportion to the body’s fat mass, and reductions in its levels may induce over-feeding
and weight gain66–68. However, the potential of leptin as a therapeutic weight-loss agent is limited since exogenous leptin delivery is associated with resistance to its effects and induces only mild physiological responses
during diet-induced obesity66–68. In humans, obesity is not linked to leptin deficiency but rather to leptin insensitivity and factors that may improve leptin sensitivity have been studied69. For example, Amylin is a hormone
that is co-secreted from beta cells along with insulin and is a powerful leptin stabilizer70,71. Additionally, the
Glucagon-Like Peptide-1 Receptor (GLP-1R) agonist Exendin-472, agonists of the melanocortin 4 receptor
(MC4R)73 and the gut hormones PYY and Cholecystokinin74,75 have all shown success in eliciting sensitization of
central leptin actions. Future pediatric studies should focus on understanding the interactions between leptin and
these hormones in an attempt to decipher the mechanisms of leptin action and potential augmentation strategies
that may be clinically relevant.
The inclusion of a non-cancer control group in comparison with SCBT, and the similar results noted between
groups provides confidence in the results and indicate that leptin is a useful adiposity biomarker in SCBT. The
determination that leptin is a predictor of total and central adiposity in SCBT is novel and provides a baseline for
future studies of adiposity in this population.
One of the limitations of this study is the lack of long-term follow-up data regarding the association of leptin
with long-term cardiometabolic outcomes. Longitudinal follow-up and a sample size that allows for subgroup
analyses based on tumor subtype will help predict which groups are at risk of adverse cardiometabolic outcomes
to allow early intervention.
In conclusion, this cross-sectional study demonstrated that leptin is a biomarker of total and central adiposity
in SCBT. Further investigation into leptin as a potential marker of future cardiovascular disease and type 2 diabetes in SCBT is needed.
It may also help stratify those in need of early interventions to prevent and treat cardiometabolic disorders in
this population of cancer survivors.

Methods

Participants.

The complete study methodology has been reported previously76,77. This is a secondary analysis of cross-sectional data from the Canadian Study of Determinants of Endometabolic Health in Children
(CanDECIDE study)76,77. The Hamilton Integrated Research Ethics Board has approved this project. Study procedures were carried out in accordance with the relevant guidelines and legal regulations. Male and female participants, who were 5 years or older, were consecutively recruited from McMaster Children’s Hospital (Hamilton,
Ontario, Canada) from November 2012 to December 2016. participants of all ethnicities with no history of autoimmune diseases or infections or having been treated with immunosuppressive therapy within 15 days of participation were eligible for recruitment into the study.
All participants provided written informed consent. Participants 16 years and older provided their own
consent. For participants between 7–15 years of age, assent as well as parental/guardian consent was obtained.
Participants under 7 years of age were included in the study with parental consent.

Anthropometric and clinical measurements.

Data on age, sex, puberty, and ethnicity were collected
using standardized questionnaires. To determine the medical history of SCBT, including diagnostic and treatment
data, we consulted medical records.
Height was measured to the closest 0.1 cm using a stadiometer and weight to the nearest 0.1 kg with an electronic scale (Seca, USA). Weight and height measurements were used to determine BMI (kg/m2). Furthermore,
BMI percentile and BMI z-score were classified using the Children’s BMI Tool for Schools78 and the Centers
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for Disease Control and Prevention (CDC) growth chart79, respectively. The Tanita body fat monitor (Tanita
Corporation, Illinois, USA) was used to measure fat mass percentage (%FM) to determine adiposity in
participants15.

Quantification of plasma leptin levels using ELISA. Fasting plasma samples were collected by centrifuging EDTA-treated whole blood at 1,500 g for 15 minutes at room temperature. Plasma samples were aliquoted
and stored in cryovials at −80 °C until further use. On the day of the assay, plasma samples were thawed on ice
and centrifuged once at 1,500 g for 15 minutes at room temperature. Plasma samples were diluted, and leptin
levels were quantified using the commercially available enzyme linked immunosorbent assay (ELISA), Human
Leptin Quantikine ELISA Kit (R&D Systems, Minneapolis, USA) as per manufacturer’s guidelines.
Statistical analysis.

SPSS versions 24.0 and 25.0 were used to perform all statistical analyses80. Categorical
variables are presented as counts (%) and continuous variables are reported as means (SD). Outliers were determined using visual inspection and box plots, and the Shapiro-Wilk test was used to determine normality of the
data distribution81. Non-normally distributed data were log-transformed for inclusion in the analyses. In the case
of missing data, multiple imputations were used.
Correlation analyses were conducted using a Pearson zero-order correlation test and partial correlation test
unadjusted and age, sex, and puberty-adjusted values. Multivariable linear regression analysis was used to determine whether leptin is associated with total or central adiposity with the independent variables including age,
sex, puberty, and cancer status. Results are reported as standardized β coefficients and associated p-values. We
also conducted unstandardized coefficients testing with resulting B values with 95% confidence intervals (CI) and
p-values. Since the results for both trended in the same direction, we report only the results of the standardized
testing in Table 3. Statistical significance was set at alpha = 0.05.
Received: 22 July 2019; Accepted: 28 February 2020;
Published: xx xx xxxx
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